Oligomer-nucleoside phosphate conjugates
View Patent ↗The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
1. A compound having the following structure:
wherein:
X is a linker when present; and
POLY is a poly(ethylene oxide) oligomer having an end capping group selected from hydroxyl and methoxy end-capping groups.
2. The compound of claim 1 , wherein the poly(ethylene oxide) oligomer is made of between 2 and 30 monomers.
3. The compound of claim 2 , wherein the poly(ethylene oxide) oligomer is made of between 2 and 10 monomers.
4. The compound of claim 1 , wherein the poly(ethylene oxide) oligomer is capped with a methoxy end-capping group.
5. The compound of claim 1 , wherein X is an ether linker.
6. The compound of claim 1 , wherein X is an ester or a phosphoester linker.
7. A composition comprising a compound of claim 1 , and optionally, a pharmaceutically acceptable excipient.
8. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form.
9. A method of treating cancer, comprising administering a compound of claim 1 to a subject in need thereof.
10. The compound of claim 1 , having the following structure
wherein n is selected from an integer from 2 to 10.
11. The compound of claim 10 , wherein n is selected from 3 and 7.
12. The method of claim 9 , wherein the cancer is selected from breast cancer, colon cancer, pancreatic cancer, lung cancer, and ovarian cancer.